| Autor: |
Pereira MB; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Sydor BG; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Memare KG; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Verzignassi Silveira TG; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Alessi Aristides SM; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Dalmarco EM; Health Sciences Center - Department of Clinical Analysis, Federal University of Santa Catarina, Campus Universitário Reitor João David Ferreira Lima, s/n°, Bairro Trindade, Florianópolis, 88040-900, SC, Brazil., Vieira Teixeira JJ; Department of Clinical Analysis & Biomedicine, State University Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil.; Post Graduation Program in Bioscience & Physiopathology, State University Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Campana Lonardoni MV; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil., Demarchi IG; Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil.; Health Sciences Center - Department of Clinical Analysis, Federal University of Santa Catarina, Campus Universitário Reitor João David Ferreira Lima, s/n°, Bairro Trindade, Florianópolis, 88040-900, SC, Brazil. |
| Abstrakt: |
Background: Nanotechnology is a promising strategy to improve existing antileishmanial agents. Objective: To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models. Materials & methods: The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting of In Vivo Experiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations. Results: Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice against Leishmania major , L. tropica or L. amazonensis . Limitations: Few studies were found to meet the eligibility criteria. Conclusion: All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies. Registration: PROSPERO register CRD42020170191. |
